An interventional study of Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT) in Glioblastoma, High-Grade Glioma (WHO III-IV) and Glioblastoma (GBM), sponsored by Medical University of Warsaw. Recruiting at 2 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Medical University of Warsaw · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Glioblastoma with a site in Poland — 8 open to participants now, 10 under way, 1 of them phase 3. Glioblastoma · Poland.
Among the 21 studies in Glioblastoma with a site in Poland, this one is the 16th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 with no phase, and was the 20th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →8 of the 21 studies in Glioblastoma with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Warsaw · Sites in Poland
Ages 18+
Medical University of Warsaw · Sites in Poland
Ages 18+
Prof. Franciszek Lukaszczyk Memorial Oncology Center · Sites in Poland
Ages 18+
Copernicus Memorial Hospital · Sites in Poland
Ages 18–70
Medical University of Warsaw · Sites in Poland
Ages 18–80
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is close to the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 96 across the 20 interventional studies, 200 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
Medical University of Warsaw is the lead sponsor of 327 studies on the registry; 88 are open to participants now.
Medical University of Warsaw has 5 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Glioblastoma with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06271421Poznan University of Medical SciencesNanoTherm In Adjuvant Therapy of Glioblastoma Multiforme | 2027-02-01 |
| NCT06975332Medical University of WarsawLocal, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression | 2027-09 |
| NCT07488754Medical University of WarsawLocal, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Glioblastoma with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups. The incidence of malignant gliomas is approximately 0.5-2 per 100,000 people annually. Standard treatments include surgical resection, radiotherapy, and chemotherapy, yet overall survival remains low, typically 1-3 years post-diagnosis. The study highlights the pressing need for novel treatment strategies, particularly given the infiltrative nature of gliomas and the potential for targeted therapies using neuropeptides.The aim of this study is to assess the efficacy and safety of local targeted therapy with [225Ac]Ac-DOTA-SP in newly diagnosed glioblastoma following standard treatment.It is an interventional study without a control group, initiated by the researcher. Patients included are aged 18-80 with WHO G3-G4 glioma post-first-line treatment, not requiring immediate surgery and meeting specific MRI criteria.Patients will receive a maximum of six cycles of [225Ac]Ac-DOTA-SP, involving pre-treatment assessments, local administration of the agent after ensuring catheter patency, and continuous monitoring. Blood tests and neurological evaluations will be performed regularly.Outcome will be assessed by measuring overall survival (OS) and progression-free survival (PFS). The study anticipates improvements in both OS and PFS when compared to current treatments, contributing to critical insights into targeted alpha therapy's effectiveness in glioblastoma.Treatment with [225Ac]Ac-DOTA-SP previously indicated few significant side effects, primarily transient issues like seizures. Patients will be closely monitored throughout the study to identify any adverse effects promptly.The estimated study duration is three years, with biological material collected for histopathological and genetic analysis during surgical reoperation.Data will be anonymized to protect patient confidentiality, stored securely, and made available only for the scope of the study.Led by Prof. Przemysław Kunert, the research team includes multiple co-investigators from neurosurgery and nuclear medicine departments.
Background Brain tumors account for approximately 1.35% of all cancers and are responsible for 2.2% of cancer-related deaths. Gliomas are the most common primary brain tumors and, depending on age group, represent 40%-90% of central nervous system tumors. The incidence of malignant gliomas is estimated at 0.5-2 cases per 100,000 persons per year. These tumors occur more frequently in men, most often in the fifth and sixth decades of life. In Poland, approximately 1,300 patients are diagnosed with gliomas annually, including about 600 with malignant disease.
Current standard treatment consists of surgery, radiotherapy, and chemotherapy. Nevertheless, prognosis remains poor, with median survival ranging from 1 to 3 years depending on tumor type. Despite treatment, disease progression commonly occurs, and chemotherapy provides only a modest extension of survival. These limitations underscore the need for novel therapeutic strategies.
Given the infiltrative nature of gliomas, an effective treatment should diffuse throughout the tumor and selectively bind to neoplastic cells. Peptide-based targeted therapy appears particularly promising in this context. Many tumors express membrane receptors at high levels, allowing the use of radioisotope-labeled peptides for diagnosis and therapy. This approach is already applied in selected lymphomas and neuroendocrine tumors.
In gliomas, particularly WHO grade II-IV, increased expression of neurokinin-1 (NK-1) receptors has been observed. Substance P, the natural ligand for NK-1 receptors, demonstrates rapid diffusion and binding to glioma cells. A derivative of substance P developed at the Institute of Nuclear Medicine, University Hospital Basel, showed that more than 95% of gliomas exhibit elevated NK-1 receptor expression, confirming its potential for targeted therapy.
Substance P may be labeled with beta-emitting isotopes such as 90Y and 177Lu. However, due to their longer tissue range, these isotopes may pose a risk to adjacent critical brain structures. This limitation prompted interest in alpha emitters such as 213Bi and 225Ac, which have high energy but very short tissue penetration.
Within the project "Use of Radioisotope-Labeled Substance P in Treating Patients with Brain Tumors" (KB/204/A/201), local treatment with alpha-emitter-labeled substance P was administered in patients with recurrent glioma. Treatment with [213Bi]Bi-DOTA-SP was well tolerated and not associated with clinically significant adverse effects. Median progression-free survival (PFS) was 2.7 months, median overall survival (OS) after recurrence was 10.9 months, and median OS from diagnosis was 23.6 months.
Because of the short half-life of 213Bi (46 minutes), subsequent studies focused on 225Ac. In a dose-escalation study of [225Ac]Ac-DOTA-SP at activities of 10, 20, and 30 MBq, treatment was also well tolerated. The maximum tolerated dose was determined to be 20 MBq. Median OS from diagnosis was 35 months, median OS from recurrence was 13.2 months, and median PFS from treatment initiation was 2.4 months.
On the basis of these encouraging findings, the present project proposes radioisotope therapy beginning 2 months after standard treatment in patients with newly diagnosed WHO grade G3-G4 glioma, with the aim of assessing whether [225Ac]Ac-DOTA-SP improves survival and delays disease progression.
Main Objective To evaluate the efficacy of local targeted therapy with the alpha-emitter-labeled neuropeptide [225Ac]Ac-DOTA-SP, administered using the forced diffusion method, in patients with newly diagnosed WHO grade G3-G4 glioma after first-line treatment.
Secondary Objective To assess the safety of local targeted therapy with [225Ac]Ac-DOTA-SP.
Study Procedures
Reoperation and Catheter Placement
Local Treatment with [225Ac]Ac-DOTA-SP
Radiopharmaceutical preparation:
Therapeutic administration:
Pre-treatment medication:
Post-administration imaging and monitoring:
SPECT/CT assessment of distribution:
If treatment is poorly tolerated, it will not be continued. Steroid therapy will be initiated if not already in place, and seizures will be managed according to standard anticonvulsant protocols.
Monitoring Before Each Subsequent Cycle and 2-4 Weeks After Administration
Therapy will be discontinued in the event of:
Study Endpoints Primary Endpoint
Progression-free survival (PFS), defined as the time to progression based on:
Secondary Endpoints
Risks and Discomforts Based on current experience, treatment with [225Ac]Ac-DOTA-SP has not been associated with clinically significant adverse effects. The most frequently reported adverse event has been seizures, although these were present before treatment in all affected patients. No clinically significant abnormalities have been observed in laboratory tests.
At present, there is no conclusive scientific evidence that the local radioactivity used in this treatment increases the risk of secondary malignancy or hereditary defects. However, efficacy as supplementary treatment after standard therapy has not yet been definitively established.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with high-grade gliomas (WHO G3-G4) after standard therapy who are treated with local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT)
Radiation: Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.
1. Number of patients experiencing clinical progression (as defined below)
Clinical progression defined by: * reduction in Karnofsky Performance Scale result below 70% OR * new focal neurological deficit or exacerbation of existing deficit OR * necessity to use or increase dexamethasone dose by 50% or more.
Time frame: From enrollment to 18 months
2. Number of patients experiencing radiological progression (as defined below)
Radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion OR * 25% or more increase in contrast-enhancing lesions despite stable or increasing steroid dose OR * significant increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumour causes.
Time frame: From enrollment to 18 months
3. Number of patients experiencing local radiological progression (as defined below)
Local radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion within 4 cm from resection cavity OR * 25% or more increase in contrast-enhancing lesions within 4 cm from resection cavity despite stable or increasing steroid dose.
Time frame: From enrollment to 18 months
Plan to share: Yes — Study protocol and anonymised clinical, radiological and molecular data regarding individual patients will be made available as supplementary materials to published articles.
Supporting information: Study protocol
Time frame: from study conclusion in Sep 2028
Access criteria: Data access will be provided to any researchers possessing access to published articles as supplementary materials or via e-mail on reasonable request.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.
Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 23 months is below that.
Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Warsaw →